NovoCure (NVCR) Operating Margin (2014 - 2026)

NovoCure has disclosed Operating Margin across 13 years of filings, most recently posting 38.73% for Q1 2026.

• Operating Margin for Q1 2026 came in at 38.73%, down 1430.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 27.19% (down 35.0% YoY), and the FY2025 annual result was 23.47%, up 470.0% from the prior year.
• Operating Margin came in at 38.73% for Q1 2026 at NovoCure, down from 23.17% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 0.59% in Q1 2022 to a low of 49.71% in Q2 2023.
• The 5-year median for Operating Margin is 24.89% (2025), against an average of 29.19%.
• Across the five-year window, Operating Margin plunged 4872 bps in 2023 and surged 2738 bps in 2024, its largest moves.
• NovoCure's Operating Margin stood at 33.46% in 2022, then fell by 16 bps to 38.66% in 2023, then declined by 2 bps to 39.25% in 2024, then jumped by 41 bps to 23.17% in 2025, then tumbled by 67 bps to 38.73% in 2026.
• The last three Operating Margin figures came in at 38.73% (Q1 2026), 23.17% (Q4 2025), and 21.54% (Q3 2025), per Business Quant data.